14-16 November 2018


Workshop A
Wednesday November 14, 2018

09.00 - 13.00
Maximizing the Chances of Immunogenicity of Neoantigen-Based Treatments to Improve Success Rates

Bioinformatics and mass spectroscopic predictions for epitope binding to MHC Class I has improved greatly. However, the immune response to selected neoantigens
are still not well understood and can be determined easily.

Attendees will learn about:

  • Why some epitopes are recognized and some are not?
  • Is selecting for driver mutations the way to go?
  • Reasoned approach to the selection of neoantigens
  • The need to characterize the pre-existing T cell response to neoantigens in patients to be treated
  • Are cross-reactive responses deleterious?
Workshops Leaders:
Antonella Vitiello
Founder & CEO
Rachel Marty
Bioinformatics Data Scientist
University of California, San Diego


Workshop B
Wednesday November 14, 2018

14.00 - 17.00
Neoantigen Selection, Prediction and Validation to Improve Target Efficacy

Identification of tumor antigens and neoantigens is critical to the success of immune targeting in next generation cancer vaccines and cell immunotherapies. A variety of methods are being employed to approach neoantigen calling.

Attendees will learn about:

  • Optimal process for neoantigen selection
  • Case studies for various methods for identification and validation of neoantigen
  • Approaches that are less costly and time consuming
  • Immune dominance of neoantigens and dual recognition of neoantigens by a single T cell receptor
Workshops Leaders:
Rongfu Wang
Professor & Director of Center for Inflammation & Epigenetics
Houston Methodist
Michal Bassani-Sternberg
Director, Immunopeptidomics Unit, Lausanne Branch, Ludwig Institute for Cancer Research
University of Lausannen


Neoantigen Manufacutring & Regulations Bootcamp
Wednesday November 14, 2018

09.00 - 15.00
Optimizing Manufacturing & Quality of Personalized Therapies from Regulatory & Technical Perspectives

Neoantigen based vaccines and cell therapies have made significant progress and as commercialization draws closer, limitations in personalised manufacturing process is causing the effective therapies to be expensive and time consuming to produce. This bootcamp brings together quality, regulatory and process development perspectives to give you a comprehensive boost in your CMC approaches.

Attendees will learn about:

  • Understanding Regulatory Requirements and Cutting Time and Cost of Manufacturing
  • Experiences and perspectives in working with FDA &EMA
  • Regulatory and Compliance Considerations in the Manufacture of Individualized Medicines
  • Approaches to release tests that cut time and cost
  • Optimizing process development
Workshops Leaders:
Erin E. Jones
Senior Vice President and Global Head of Regulatory Affairs and Quality Assurance
Gritstone Oncology
David Pajerowski
Director, Process Development & CMC, Personalized Vaccines Unit
Moderna Therapeutics